-
Mashup Score: 0
PURPOSE To report the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) Florence phase III trial comparing whole-breast irradiation (WBI) to APBI in early-stage breast cancer. PATIENTS AND METHODS The primary end point was to determine the 5-year difference in ipsilateral breast tumor recurrence (IBTR) between 30 Gy in 5…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19.
__________
The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery.
After…
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19: Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a… https://t.co/qU03L32jGr https://t.co/Y6jTcQAPrX
-
Mashup Score: 0NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals - 4 year(s) ago
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
Source: www.jwatch.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
NEJM Journal Watch Oncology and Hematology Editor-in-Chief Dr. William Gradishar was on hand at the recent San Antonio Breast Cancer Symposium to report the latest findings in #breastcancer research. https://t.co/wa0wgg0YAy @SABCSSanAntonio #SABCS19 https://t.co/6b1vNu1rXU
-
-
Mashup Score: 0
‘Best of SABCS’ From Jame Abraham, MD, FACP Jame Abraham, MD, FACP Each year, The ASCO Post asks Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most…
Source: www.ascopost.comCategories: Hem/Onc News and JournalsTweet-
Updates From Selected Clinical Trials in Breast Cancer: ‘Best of SABCS’ From Jame Abraham, MD, FACP https://t.co/pUVnysq2G9 #bcsm #oncology #cancer #SABCS19 https://t.co/8yG3fWPjAv
-
-
Mashup Score: 0The FLEX Real World Data #SABCS19 @BaptistHealthSA - 4 year(s) ago
Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer.
Source: www.oncologytube.comCategories: Hem/Onc News and JournalsTweet-
The FLEX Real World Data #SABCS19 @BaptistHealthSA: Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer. https://t.co/GlV80N3KM0 https://t.co/TCLwZz36uA
-
-
Mashup Score: 0
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19.
__________
The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery.
After…
Source: www.oncologytube.comCategories: Hem/Onc News and JournalsTweet-
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19: Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a… https://t.co/dr6USiBFrx https://t.co/xhYtpQaraS
-
Mashup Score: 0Frequently Asked Questions on the Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer #SABCS19 - 4 year(s) ago
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to IV paclitaxel: a Phase III clinical study in metastatic breast cancer.
Source: www.oncologytube.comCategories: Hem/Onc News and JournalsTweet-
Frequently Asked Questions on the Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer #SABCS19: Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to IV paclitaxel: a… https://t.co/sJtfzeYQ6Q https://t.co/x5fsEtGpTs
-
-
Mashup Score: 0Agendia Presents New Data at #SABCS19 in Breast Cancer - 4 year(s) ago
William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer.
Source: www.oncologytube.comCategories: Hem/Onc News and JournalsTweet-
Agendia Presents New Data at #SABCS19 in Breast Cancer: William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer. https://t.co/iOpdlkARMX https://t.co/PTlkHUg5LB
-
-
Mashup Score: 0Neoadjuvant pembrolizumab benefits patients with high-risk triple-negative breast cancer - 4 year(s) ago
SAN ANTONIO — The addition of pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased pathologic complete response among patients with high-risk disease, according to results of the KEYNOTE-522 trial presented at San Antonio Breast Cancer Symposium.These included patients with stage IIIa or stage IIIb disease, as well as those with lymph node involvement.
Source: bit.lyCategories: Hem/Onc News and JournalsTweet-
Neoadjuvant pembrolizumab @Merck benefits patients with high-risk triple-negative breast cancer. Study in today’s @NEJM details results of the phase 3 KEYNOTE-522 trial, as previously reported by @HemOncToday when presented at last year’s #SABCS19 https://t.co/n5mnZRibgR @QMBCI https://t.co/SsMtb68nVl
-
-
Mashup Score: 6
PURPOSE Platinum compounds have activity in triple-negative breast cancer (TNBC) in germline BRCA mutation carriers (BRCA carriers). Limited data exist for estrogen receptor (ER)–positive (+) breast cancer among BRCA carriers. INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus…
Source: Journal of Clinical OncologyCategories: Hem/OncsTweet-
One of the most important abstracts at #SABCS19 now published in @ASCO_pubs: the #TBCRC031 #INFORM trial showing no superiority of neoadjuvant #cisplatin vs. #doxorubicin + #cyclophosphamide in #BRCA-mutated #BreastCancer patients #OncoAlert #bcsm @ASCO https://t.co/4JnVM4bK0q
-
-
-
So important long-term data from the phase III #APBI-IMRT-Florence #trial published in @ASCO_pubs by my great friend @Icro_Meattini and team on #radiotherapy de-escalation: congratulations! #OncoAlert #BreastCancer #bcsm #ItalianPride #SABCS19 @ASCO #RT https://t.co/GUoWA7c06C